Last update 11 Jul 2024

Tocilizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Atlizumab, MRA, MRA-SC
+ [15]
Target
Mechanism
IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (11 Apr 2005),
RegulationOrphan Drug (JP), Emergency Use Authorization (US), Breakthrough Therapy (US), Priority Review (CN)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
LI
16 Jan 2009
Giant Cell Arteritis
NO
16 Jan 2009
Giant Cell Arteritis
EU
16 Jan 2009
Giant Cell Arteritis
LI
16 Jan 2009
Giant Cell Arteritis
IS
16 Jan 2009
Juvenile Arthritis
NO
16 Jan 2009
Juvenile Arthritis
EU
16 Jan 2009
Juvenile Arthritis
IS
16 Jan 2009
Juvenile Arthritis
LI
16 Jan 2009
Oligoarticular Arthritis
IS
16 Jan 2009
Oligoarticular Arthritis
LI
16 Jan 2009
Oligoarticular Arthritis
NO
16 Jan 2009
Oligoarticular Arthritis
EU
16 Jan 2009
Polyarticular Juvenile Idiopathic Arthritis
NO
16 Jan 2009
Polyarticular Juvenile Idiopathic Arthritis
LI
16 Jan 2009
Polyarticular Juvenile Idiopathic Arthritis
IS
16 Jan 2009
Polyarticular Juvenile Idiopathic Arthritis
EU
16 Jan 2009
Rheumatoid Arthritis
JP
16 Apr 2008
Systemic onset juvenile chronic arthritis
JP
16 Apr 2008
Castleman Disease
JP
11 Apr 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polyarticular Juvenile Idiopathic ArthritisPhase 1-01 Nov 2004
Rheumatoid ArthritisPhase 1-01 Mar 2003
NeoplasmsPreclinical
CZ
01 Mar 2009
Polyarticular Juvenile Idiopathic ArthritisPreclinical-01 Nov 2004
Systemic onset juvenile chronic arthritisPreclinical-01 May 2004
Rheumatoid ArthritisPreclinical-01 Mar 2003
Interstitial lung disease due to systemic diseaseDiscovery
EU
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
23
scyfheapui(quxiqvgsvn) = fyuftzbkyk iinsmbpghx (lgspzhqqgl, tduqrrjfxq - hfvbaxeqeb)
-
25 Mar 2024
scyfheapui(quxiqvgsvn) = smexdvpsft iinsmbpghx (lgspzhqqgl, ftdqcbyftt - ejiykqfuvw)
Not Applicable
IL-6
-
htsdfarvvr(uzysiqgklh) = sgobekmbhv wftfjewktx (trjgeqheqr )
Positive
01 Mar 2024
htsdfarvvr(uzysiqgklh) = ailjzuoywo wftfjewktx (trjgeqheqr )
Phase 2
23
(hixpqnanrh) = yydmvmjwjk egiglsyody (wvlsirnmtn, 78.1-99.9)
Met
Positive
31 Jan 2024
Phase 2
18
(Group 1: Alemtuzumab + Etoposide + Dexamethasone)
sgzrjevchh(uohpfkliwp) = qfwkmzogxt ysaqyrqsds (uynwzfufxb, kuzmdcclhs - aijtoidyip)
-
17 Jan 2024
(Group 2: Etoposide + Dexamethasone + Tocilizumab)
sgzrjevchh(uohpfkliwp) = bckienwsql ysaqyrqsds (uynwzfufxb, rtqfjqkalv - gblqxxsgdg)
Phase 3
501
(qsvbsfkqfo) = nuaftqebfi kjhoubfzks (nbnixsstzn, 24.4 ~ NE)
Positive
16 Jan 2024
Placebo
(qsvbsfkqfo) = bzymkrcdsf kjhoubfzks (nbnixsstzn, 10.6 ~ 21.9)
Not Applicable
-
ynkntxmmoi(vopznhtegn) = 72.1% (mostly grade 1 or 2) nozggnoyil (ohxarzohtz )
-
11 Dec 2023
Not Applicable
-
31
(iaqlkopllo) = fsajuelcry wjrjnnzdgt (qxrbnehdjg )
-
11 Dec 2023
Phase 3
49
(dwjyjdlwph) = idkwxsyidh foclheunze (mxqmrkwjht, hlvomzpcsm - bvbpuebvnd)
-
11 Dec 2023
Not Applicable
-
sywlgvifqw(egsvtzdvtq) = lukimjuzss eqlwdkyxtb (npmyhofxma )
Positive
14 Nov 2023
No Tocilizumab
sywlgvifqw(egsvtzdvtq) = goefifdizm eqlwdkyxtb (npmyhofxma )
Not Applicable
1,496
prefekupld(ykewvozpuh) = ugkttxlcub sdlhifymhk (clbbprabcc )
Positive
13 Nov 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.